Icosavax, Inc. (ICVX)
Feb 20, 2024 - ICVX was delisted (reason: acquired by AstraZeneca)
15.31
0.00 (0.00%)
Last trade price
Icosavax Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Icosavax stock has a target of 25, which predicts an increase of 63.29% from the current stock price of 15.31.
Analyst Consensus: Buy
* Price targets were last updated on Oct 2, 2023.
Analyst Ratings
The average analyst rating for Icosavax stock from 2 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '23 | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 2, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $28 | Strong Buy | Initiates | $28 | +82.89% | Nov 17, 2023 |
| Oppenheimer | Oppenheimer | Buy Reiterates $25 | Buy | Reiterates | $25 | +63.29% | Oct 2, 2023 |
| Oppenheimer | Oppenheimer | Buy Reiterates $27 | Buy | Reiterates | $27 | +76.36% | Apr 25, 2023 |
| Oppenheimer | Oppenheimer | Buy Initiates $27 | Buy | Initiates | $27 | +76.36% | Jan 4, 2023 |
Financial Forecast
Revenue This Year
n/a
from 582.00K
Revenue Next Year
n/a
EPS This Year
-2.18
from -2.31
EPS Next Year
-2.15
from -2.18
Revenue Forecast
| Revenue | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 5.3M | 201.4M | 507.5M | 710.9M |
| Avg | n/a | n/a | 1.0M | 50.2M | 203.2M | 297.0M |
| Low | n/a | n/a | n/a | n/a | 4.9M | 68.6M |
Revenue Growth
| Revenue Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | - | - | - | 19,649.0% | 911.0% | 249.8% |
| Avg | - | - | - | 4,821.2% | 304.8% | 46.2% |
| Low | - | - | - | - | -90.2% | -66.2% |
EPS Forecast
| EPS | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | -2.02 | -1.77 | -2.10 | 0.23 | 3.87 | 2.19 |
| Avg | -2.18 | -2.15 | -2.42 | -1.81 | 0.88 | 2.13 |
| Low | -2.26 | -2.35 | -2.65 | -3.69 | -1.92 | 2.05 |
EPS Growth
| EPS Growth | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| High | - | - | - | - | - | 148.7% |
| Avg | - | - | - | - | - | 141.6% |
| Low | - | - | - | - | - | 132.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.